ArticlePloS one2015
Nanocytological field carcinogenesis detection to mitigate overdiagnosis of prostate cancer: a proof of concept study.
Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 31 citations in OpenAlex.
- Quantification of structural heterogeneity in H&E stained clear cell renal cell carcinoma using refractive index tomography.Biomedical optics express · 2023Article
- Prostate cancer histopathology using label-free multispectral deep-UV microscopy quantifies phenotypes of tumor aggressiveness and enables multiple diagnostic virtual stains.Scientific reports · 2022Article
- Deep UV Microscopy Identifies Prostatic Basal Cells: An Important Biomarker for Prostate Cancer Diagnostics.BME frontiers · 2022Article
- Focal therapy for localized prostate cancer in the era of routine multi-parametric MRI.Prostate cancer and prostatic diseases · 2020Review
- Multimodal interference-based imaging of nanoscale structure and macromolecular motion uncovers UV induced cellular paroxysm.Nature communications · 2019Article
- Tissue spatial correlation as cancer marker.Journal of biomedical optics · 2019Article
- Advances in the computational and molecular understanding of the prostate cancer cell nucleus.Journal of cellular biochemistry · 2018Review
- Correlating colorectal cancer risk with field carcinogenesis progression using partial wave spectroscopic microscopy.Cancer medicine · 2018Article
- Disorder strength measured by quantitative phase imaging as intrinsic cancer marker in fixed tissue biopsies.PloS one · 2018Article
- Measuring Nanoscale Chromatin Heterogeneity with Partial Wave Spectroscopic Microscopy.Methods in molecular biology (Clifton, N.J.) · 2018Article
- Article
- Macrogenomic engineering via modulation of the scaling of chromatin packing density.Nature biomedical engineering · 2017Article
- The transformation of the nuclear nanoarchitecture in human field carcinogenesis.Future science OA · 2017Review
- Colocalization of cellular nanostructure using confocal fluorescence and partial wave spectroscopy.Journal of biophotonics · 2017Article
- Review of interferometric spectroscopy of scattered light for the quantification of subdiffractional structure of biomaterials.Journal of biomedical optics · 2017Review
- The Global Relationship between Chromatin Physical Topology, Fractal Structure, and Gene Expression.Scientific reports · 2017Article
- Procedures for risk-stratification of lung cancer using buccal nanocytology.Biomedical optics express · 2016Article
- Nanoscale refractive index fluctuations detected via sparse spectral microscopy.Biomedical optics express · 2016Article
- Automated Cell Selection Using Support Vector Machine for Application to Spectral Nanocytology.BioMed research international · 2016Article
- Harnessing novel modalities: field carcinogenesis detection for personalizing prostate cancer management.Future oncology (London, England) · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 3 institutions in 1 country.
Funding
Abstract
purposeTo determine whether nano-architectural interrogation of prostate field carcinogenesis can be used to predict prognosis in patients with early stage (Gleason 6) prostate cancer (PCa), which is mostly indolent but frequently unnecessarily treated. MATERIALS AND
methodsWe previously developed partial wave spectroscopic microscopy (PWS) that enables quantification of the nanoscale intracellular architecture (20-200 nm length scale) with remarkable accuracy. We adapted this technique to assess prostate needle core biopsies in a case control study from men with Gleason 6 disease who either progressed (n = 20) or remained indolent (n = 18) over a ~3 year follow up. We measured the parameter disorder strength (Ld) characterizing the spatial heterogeneity of the nanoscale cellular structure and nuclear morphology from the microscopically normal mucosa ~150 histologically normal epithelial cells.
resultsThere was a profound increase in nano-architectural disorder between progressors and non-progressors. Indeed, the Ld from future progressors was dramatically increased when compared to future non-progressors (1±0.065 versus 1.30±0.0614, respectively p = 0.002). The area under the receiver operator characteristic curve (AUC) was 0.79, yielding a sensitivity of 88% and specificity of 72% for discriminating between progressors and non-progressors. This was not confounded by demographic factors (age, smoking status, race, obesity), thus supporting the robustness of the approach.
conclusionsWe demonstrate, for the first time, that nano-architectural alterations occur in prostate cancer field carcinogenesis and can be exploited to predict prognosis of early stage PCa. This approach has promise in addressing the clinically vexing dilemma of management of Gleason 6 PCa and may provide a paradigm for dealing with the larger issue of cancer overdiagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.